This should be the company's tag line:
" What makes Zilosul special is not it’s effectiveness, but the legal and regulatory framework that allows it to be made available to humans, which is also a wide and deep moat against competitors."
Accessing knock-offs and counterfeits is the least of our concerns. Most widely used drug manufacturers need to monitor for illegal usage and slippage by dubious operators. Furthermore, reimbursements would also ensure there will be very little financial incentive to seek out alternative sources.
This should be the company's tag line:" What makes Zilosul...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |